Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.69 |
| ▸ | HTR3A | P46098 | 2/20 | 0.69 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.69 |
| ▸ | HTR3B | O95264 | 1/20 | 0.69 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.69 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL29424286 | 0.95 | HTR4 (0.63) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| Fumaric Acid SCHEMBL29424288 | 0.95 | HTR4 (0.63) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7393687 | 0.92 | HTR4 (0.74) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7434513 | 0.89 | HTR4 (0.67) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7430644 | 0.86 | HTR4 (0.54) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7430400 | 0.84 | PARP1 (0.51) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7438457 | 0.83 | HTR4 (0.64) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7436075 | 0.83 | HTR4 (0.72) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7435639 | 0.82 | HTR3A (0.55) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7430663 | 0.82 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5442077-A | Benzo[B]Furancarboxamide derivatives, process for the preparation of same and use thereof for improving hypermotility | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1995-08-15 | — | — | US | claimed |
| EP-0640602-A1 | Benzo[b]furancarboxamide derivatives, process for their preparation and their use as gastrointestinal mobility-enhancing agents | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1995-03-01 | — | — | EP | claimed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-3884935-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2020237096-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | ARDELYX, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200038475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| EP-3492106-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20160184387-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | CHARMOT DOMINIQUE (US) | 2016-06-30 | — | — | US | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-5442077-A | Benzo[B]Furancarboxamide derivatives, process for the preparation of same and use thereof for improving hypermotility | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1995-08-15 | — | — | US | disclosed |
| EP-0640602-A1 | Benzo[b]furancarboxamide derivatives, process for their preparation and their use as gastrointestinal mobility-enhancing agents | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184387-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885HTR3A 991/4885HTR3E 730/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | HTR4 672/4885HTR3A 574/4885HTR3E 1038/4885 |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 3153/4885HTR3A 1919/4885HTR3E 1253/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | HTR4 3498/4885HTR3A 3141/4885HTR3E 2780/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | HTR4 1626/4885HTR3A 1245/4885HTR3E 1685/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885HTR3A 991/4885HTR3E 730/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 3153/4885HTR3A 1919/4885HTR3E 1253/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR4 521/4885HTR3A 353/4885HTR3E 504/4885 |
| US-20200038475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885HTR3A 991/4885HTR3E 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.